Priming of mice with complexes of antigen coupled to muramyl dipeptide and monoclonal anti-muramyl dipeptide antibodies enhanced the adjuvant activity of muramyl dipeptide on the humoral response to the antigen. The enhancement did not occur with free (uncoupled) muramyl dipeptide and required the presence of an adjuvant-active hapten within the complex as well as the Fc fragment of the monoclonal antibody. This system proved highly effective in eliciting antibodies to synthetic weak immunogens whereas muramyl dipeptide, on its own, exerts very little or no adjuvant activity. The effect was not due to a general polyclonal activation and was restricted to the antigen coupled to the synthetic adjuvant. Possible pathways involved in this phenomenon are discussed.
The regulation of cellular and humoral immune responses by antibodies has been extensively investigated in the last decade (reviewed in references 37 and 38) . The mechanisms involved in such regulation are quite complex and depend on the system used. In none of these studies was the antigen also an adjuvant. Moreover, antibodies or some of their fragments possess adjuvant or immunomodulating properties in their own right (14, 20, 27) .
Muramyl dipeptide (MDP, N-acetylmuramyl-L-alanyl-Disoglutamine) has been shown to be the minimal structure of a bacterial cell wall peptidoglycan that can substitute for mycobacteria in Freund complete adjuvant (10) . The 492-dalton synthetic copy of this adjuvant has been successfully utilized in the preparation of certain synthetic vaccines (3, 8) . Besides its adjuvant activity, MDP was found to exert a variety of immunomodulatory and neuromodulatory effects in several mammalian hosts (2, 12, 19) . When monoclonal antibodies to MDP were produced, it seemed appropriate to study their effects on certain biological activities of MDP. In this respect anti-MDP antibodies were found previously to enhance by 100-to 1,000-fold MDP-induced macrophage activation in vitro (22) .
In this study, we report the modulation of the in vivo adjuvant activity of MDP with monoclonal antibodies to this synthetic glycopeptide. Enhancement of the kinetics and the magnitude of the MDP adjuvant effect on the response to protein antigens was observed upon priming of mice with complexes of MDP coupled to an antigen and anti-MDP antibodies. This system proved highly effective in eliciting antibodies to weak immunogens and even to neutral synthetic antigens, whereas MDP on its own exerted very little or no adjuvant effect. Some aspects of the mechanism of this enhancement will be presented.
MATERIALS AND METHODS
Antigens. Human albumin (HA) was purchased from Calbiochem (La Jolla, Calif.). The polypeptide fragment of type 24 streptococcal M protein (M24) and the synthetic (4, 5) .
Control monoclonal antibodies with anti-DNP specificity, namely, U-7-27 (IgG2a) and U-12-5 (IgG2b), were kindly provided by Z. Eshhar of the Weizmann Institute, Rehovot, Israel, and were prepared as previously described (11) .
An ammonium sulfate precipitate (50%) of ascitic fluid from mice immunized with each clone, referred to as ascitic immunoglobulin, was prepared and used in most experiments. An IgG fraction of the antibodies, used in some experiments, was prepared by passing the ascitic immunoglobulin over an S-200 column (Pharmacia Fine Chemicals, Piscataway, N.J.) and collecting the 160,000-dalton peak recognizing the corresponding hapten.
Preparation of F(ab')2. An IgG fraction of the monoclonal anti-MDP (clone M-52-11) was dialyzed against 0.1 M sodium acetate buffer (pH 4.5). To 25 mg of IgG in 3 ml, 1 mg of solid pepsin (Sigma) was added and incubated at 37°C for 18 h. The pH was then adjusted to 8.0 with 1 M Tris, and the digested IgG was dialyzed against PBS (pH 7.4). Removal of Fc fragments and undigested IgG was accomplished by passing the preparation twice over a 10-ml Sepharoseprotein A column (Pharmacia). The unbound F(ab')2 fragment was collected and tested for its purity by an enzymelinked immunosorbent assay (ELISA) technique (described below) employing rabbit anti-mouse subclass-specific antisera (Litton Bionetics, Inc., Charleston, S. C.). The pure F(ab')2 preparation of M-52-11 had the same activity in binding to HRPO-MDP-Lys2 as undigested IgG of the same antibody.
Immunization. Female BALB/c mice 6 to 8 weeks old were purchased from Iffa-Credo (L'Arbresle, France) and were immunized by the following protocol, unless otherwise mentioned. Groups of mice (five to seven per group) were primed intraperitoneally (i.p.) with either 50 ,ug of antigen, 50 jig of antigen-hapten conjugate (50 jig of antigen in the conjugate), or 50 jig of the conjugate mixed with monoclonal antihapten antibody (0.8 to 500 ,ug). Mice were bled from the orbital plexus vein 7, 14, and 28 days after priming, boosted (i.p.) on day 28 with 50 ,ug of antigen, and bled again 7 days after the boost (35-day response). Sera were separated and stored at -20'C until tested. Preliminary experiments for immunization with complexes showed that a ratio (weight/weight) of hapten to antihapten in the range of 1/5 to 1/50 produced a marked effect whenever the effect existed. Thus, in all experiments, unless otherwise mentioned, 100 jig of ascitic immunoglobulin of monoclonal antihapten antibody was mixed with 50 ,ug of the conjugate (containing between 2.6 and 19 ,ug of hapten) and injected into one mouse.
ELISA. The ELISA technique has been described in detail elsewhere (6) . Briefly, 10 ,ig of antigen (untreated) per ml was coated onto wells of flat-bottomed micro-ELISA plates (Dynatech Laboratories, Inc., Alexandria, Va.) for 3 h at 4°C. After the plates were washed with PBS containing 0.05% Tween 20 (PBS-Tween), fourfold dilutions of test sera ranging from 1/400 to 1/409,600 were added in duplicate or triplicate to the wells and incubated for 2 h at room temperature. After further washing with PBS-Tween, rabbit antimouse immunoglobulin (total class or subclass specific; Litton Bionetics) conjugated to HRPO (30) was added to the wells and incubated overnight at 4°C. The anti-mouse immunoglobulin-HRPO conjugate was used at 1/10,000, and the anti-mouse class-or subclass-specific-HRPO conjugates were used at 1/1,000 dilution. The unbound conjugate in the wells was then washed off with PBS-Tween, and the bound enzyme was assayed with O-phenylenediamine and H202 as the substrate. The reaction was stopped after 30 min by adding 12.5% H2SO4, and the optical density (OD) was the ELISA. Thus, the fold increase in antibody levels was calculated as (OD after immunization at 1/X dilution)/(OD before immunization at 1/400 dilution) x (X/400). This calculation was used after being verified with dilutions of known antibody content.
Statistical analysis. Student's t test was used for statistical evaluation of the differences in antibody levels between groups based on the average of at least two readings for each individual serum per group (minimum five mice per group). Variations in OD values between duplicates were negligible (<5%); thus, where the results of antibody levels are presented for the pool of a group, differences of 10% or more between groups were found to be significant (P < 0.05).
RESULTS
Effect of monoclonal aniti-MDP antibodies on the adjuvant activity of MDP. Several experiments were performed to determine whether priming with HA-MDP-Lys mixed with monoclonal anti-MDP antibody could modulate the adjuvant activity of MDP. The results of three such experiments employing three different conjugates, HA-MDP-Lys6, HA-MDP-Lysl6, and HA-MDP-Lys32, are presented in Table 1 .
Higher levels of anti-HA antibodies were detected in both the primary and the secondary responses in mice primed with any of the conjugates (HA-MDP-Lys) as compared with mice primed with HA on its own, thus confirming the adjuvant activity of MDP. Moreover, priming with complexes of HA-MDP-Lys and anti-MDP antibodies enhanced the adjuvanticity of MDP and induced a further increase in the anti-HA response (Table 1 ). This enhancement of anti-HA antibodies was not class specific and was observed with all four subclasses of IgG (data not shown). The enhancing effect was shown to be MDP-anti-MDP specific, since (i) priming with HA (without MDP) and anti-MDP antibody did not enhance the response to the antigen, and (ii) priming with HA-MDP-Lys32 mixed with a monoclonal anti-DNP antibody did not modify the anti-HA response (Table 1 Table 3 . Similar to the previous results and in the absence of MDP, priming with complexes of HA-DNP-Lys and anti-DNP antibodies did not enhance the response to HA over that induced by the conjugate alone. However, when MDP was injected into mice together with the complexes, an enhancement of the adjuvant effect of MDP on the anti-HA response was noted early in the primary response (day 14). This effect was not maintained either in the late primary response (day 28; data not shown) or in the secondary response, indicating that the observed enhancement was only on the kinetics and not on the magnitude of the antibody response to HA. Differences in the avidity of the antibodies to their haptens could account for the lack of enhancement of the response to the carrier after immunization with carrier-haptenantihapten complexes. Consequently the avidities of the four monoclonal antibodies to their respective free or conjugated haptens were measured in an ELISA by using an inhibition of binding of a known concentration of HRPO-labeled hapten to the antihapten antibody (Table 4 (Fig. 1) . Similar effects were observed later after primary or secondary immunization. This indicated that the Fc part of the anti-MDP antibody was an essential constituent of the complex for the enhancement of the anti-HA response.
Effect of boosting with HA-MDP-anti-MDP complexes on an ongoing response to HA. To investigate whether the enhancement of the adjuvanticity of MDP with the monoclonal anti-MDP antibody was restricted to the priming step, the following experiments were performed. Mice (seven per group) were primed with HA and were boosted 3 weeks later with either HA, HA plus anti-MDP, HA-MDPLys32, or HA-MDP-Lys32 plus anti-MDP. Other groups of mice were primed with HA-MDP-Lys32 and were boosted 3 weeks later with either the conjugate alone or with a complex of the conjugate and monoclonal anti-MDP antibody. The response to HA was measured 7 days after the boost. The results of a pool of two experiments are presented in Fig. 2 . In mice primed with HA, a boost with complexes of HA-MDP-Lys-anti-MDP did not enhance the anti-HA response over a boost with the conjugate alone (Fig. 2) . However, in mice primed with HA-MDP-Lys32, a boost with the complexes induced a significantly higher (P < 0.01) anti-HA secondary response compared with a boost with the conjugate on its own (Fig. 2) . The enhancement by complexes of the MDP adjuvant effect in a strict secondary Enhancement of the adjuvant activity of MDP to a bacterial cell wall protein or to synthetic peptides with monoclonal anti-MDP antibody. To determine whether the enhancement of the adjuvant activity of MDP by complexes was restricted to the specific antigen chosen (HA), we utilized a similar system employing a streptococcal cell wall protein, M24 (33,500 daltons). When used as antigen, 50 ,ug of M24 protein, on its own, induced weak primary (10-fold increase) and secondary (28-fold increase) responses. However, when coupled to MDP-Lys and the conjugate (M24-MDP-Lys8) used as antigen, the antibody response to M24 was potentiated (Fig. 3a) due to the adjuvant effect of MDP (26-and 532-fold increases in the primary and secondary responses, respectively). This response was not modified when the conjugate was administered mixed with monoclonal anti-DNP antibody (U-7-27). However, the adjuvanticity of MDP on the response to M24 was highly enhanced when mice were primed with complexes of M24-MDP-Lys8 and anti-MDP antibody (M52-11). The enhancement was still marked in the secondary response after a boost with the conjugate alone (Fig. 3a) .
To further investigate the possible use of antigen-MDPanti-MDP complexes in enhancing antibody responses to small, weakly inmmunogenic, defined synthetic peptides, we studied the response to the S-CB7 peptide fragment (4,272 daltons) of M24 protein. Immunization of mice with 50 ,ug of S-CB7 did not induce in our hands detectable antibodies to the peptide, in either a primary or a secondary response. Priming and boosting with 50 ,ug of a conjugate of S-CB7-MDP2 elicited no detectable antipeptide antibodies in the primary response and very low levels in the secondary response (Fig. 3b) . Similarly, a lack of anti-S-CB7 antibodies was observed in mice primed with the same conjugate mixed with monoclonal anti-DNP antibody. In contrast, the immunogenicity of the S-CB7 peptide was highly potentiated upon priming with a complex of S-C37-MDP2 and anti-MDP antibody. Boosting on day 28 with the conjugate alone resulted in a very strong secondary response (day 35) to the peptide only in mice that were primed with the complex. Priming with MDP-A-L-anti-MDP complexes induces antibodies to the neutral non-immunogenic A-L chain with no evidence of polyclonal activation. Experiments were performed to answer the following three questions. (i) Does priming with complexes of MDP-A-L-anti-MDP elicit antibody response to the neutral, non-immunogenic A-L chain? (ii) Do MDP and anti-MDP need to be administered as preformed complexes for the enhancing effect to occur? (iii) Does priming with such complexes induce a general polyclonal activation? The answers to these questions are presented as the results of three experiments in Fig. 4 . In experiment 1, mice were primed (i.p.) with complexes of MDP-A-L (25 ,ug containing 5 ,ug of MDP) and anti-MDP (100 ,ug) in the presence of 50 ,ug of HA. In experiments 2 and 3, the monoclonal antibodies were injected, i.p. and intravenously, respectively, 2 h before i.p. (37, 38) . This regulatory effect was found to be dependent on several criteria such as class (13, 29, 32) , affinity (39) , and Fc fragment of the passive antibody (1, 13) (Table 2) . Moreover, when complexes of HA-DNP and anti-DNP antibodies were administered together with an adjuvant (MDP), an enhancement in the kinetics of the response to the carrier (HA) was observed (Table 3) . Thus, it appears likely that the presence of an adjuvant in the priming step plays an important role in dictating the outcome of the response to antigen-antibody complexes. This is documented further by the results in Fig. 2 whereby mice primed with HA-MDP, and not those primed with HA alone, showed a unique enhancement of the secondary response to the antigen upon boosting with complexes of HA-MDP and anti-MDP antibody. These results suggested that a certain type of helper cell is primed by the adjuvant and is essential for enhancing the antibody response. Such a cell has been described by Maillard and Bloom (25) as a T-cell which, in the presence of the adjuvant, produces soluble factors that mediate the enhancing effect. The requirement for an adjuvant in our study may also explain the findings of other workers using the non-adjuvant-active hapten (DNP) and reporting an enhanced response to the carrier after priming with complexes of carrier hapten and antihapten antibodies (15, 31, 32) . In these reports, an adjuvant such as Freund complete adjuvant or Bordetella pertussis was always used either at the priming step or for preparing helper T-cells in transfer experiments.
The most striking aspect of priming with complexes of antigen-MDP and anti-MDP antibody is the ability to induce strong humoral responses to very weak immunogens. Immunization with conjugates of MDP coupled to either the synthetic peptide S-CB7 or to the synthetic neutral A-L chain did not induce a detectable primary antibody response to the carrier. In contrast, when anti-MDP antibodies were mixed with either conjugate and used for priming mice, a detectable anticarrier response was induced within 7 days (Fig. 3 and 4) . This effect was restricted to the antigen within the complex and occurred even when the anti-MDP antibody was passively administered 2 h before the conjugate (Fig. 4) . These findings are of potential importance for the field of synthetic vaccines, especially where synthetic fragments of antigens are known to be weak immunogens.
The mechanism of action of MDP as an adjuvant is not fully understood. However, taking the above-mentioned facts into consideration, one can predict several pathways for the enhancement of the adjuvanticity of MDP with VOL. 49, 1985 on October 28, 2017 by guest http://iai.asm.org/ Downloaded from anti-MDP antibody. The simplest explanation would be that priming with MDP-containing complexes facilitates the uptake of the antigen-MDP conjugate, through the Fc fragment of the bound antibody, by antigen processing and presenting cells. This can serve two purposes: (i) concentrating the antigen in an immunogenic form at strategic points in the lymphoid system and (ii) delivering MDP to the macrophage, which is known as one of the major target cells for this synthetic adjuvant (23) . Several approaches to improve MDP delivery, such as micropumps (17) or liposomes (18, 36) , have been utilized. Complexing with antibody could be another approach that has been shown to enhance by 1,000-fold the MDP-induced macrophage activation in vitro (22) .
Another pathway by which anti-MDP antibody could enhance the adjuvanticity of MDP is the generation of helper T-cells. Our results showing enhancement of the secondary response to HA, on boosting with complexes (HA-MDP and anti-MDP) only in mice that were primed with the adjuvant, argue in favor of this pathway. These results also eliminate the possibility of a direct effect on B-cells by complexes as the mechanism of enhancement. Further experiments are being pursued to establish the exact mechanism at the cellular level of this enhanced adjuvant activity by antibody. However, it is most likely that a combination of pathways such as enhanced antigen processing and localization, enhanced macrophage activation through better delivery of MDP and through an Fc signal, and enhanced priming of helper T-cells, will account for the described phenomenon.
